AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:00:42 2024-04-26 pm EDT			5-day change	1st Jan Change
158.1 ^USD	-5.47%		-5.20%	+1.79%

07:15pm	News Highlights : Top Company News of the Day - Friday at 1 PM ET	DJ
06:27pm	Top Midday Stories: Google Announces First-Ever Dividend; Oil Giants Down on Earnings Misses; Second Norfolk Southern Union Backs Activist Investor's Board Candidates	MT

AbbVie to Host Second-Quarter 2022 Earnings Conference Call

July 11, 2022 at 09:24 am EDT

NORTH CHICAGO - AbbVie (NYSE: ABBV) will announce its second-quarter 2022 financial results on Friday, July 29, 2022, before the market opens.

AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Contact:

Frank Benenati

Tel: (224) 688-4169

Email: Frank.Benenati@abbvie.com

Latest news about AbbVie Inc.

News Highlights : Top Company News of the Day - Friday at 1 PM ET	01:15pm	DJ
Top Midday Stories: Google Announces First-Ever Dividend; Oil Giants Down on Earnings Misses; Second Norfolk Southern Union Backs Activist Investor's Board Candidates	12:27pm	MT
News Highlights : Top Company News of the Day - Friday at 11 AM ET	11:17am	DJ
Sector Update: Health Care Stocks Mixed Premarket Friday	09:43am	MT
Well, it isn't as bad as feared...	09:16am
News Highlights : Top Company News of the Day - Friday at 9 AM ET	09:16am	DJ
Transcript : AbbVie Inc., Q1 2024 Earnings Call, Apr 26, 2024	09:00am
AbbVie raises annual targets	08:32am	CF
AbbVie Lifts Outlook After 1Q Revenue Unexpectedly Rises	08:26am	DJ
AbbVie's Q1 Adjusted Earnings Fall, Net Revenue Rises; 2024 Adjusted Profit Outlook Lifted	08:10am	MT
Earnings Flash (ABBV) ABBVIE Reports Q1 Revenue $12.31B, vs. Street Est of $11.94B	07:54am	MT
Earnings Flash (ABBV) ABBVIE Reports Q1 EPS $2.31, vs. Street Est of $2.26	07:53am	MT
AbbVie Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07:43am	CI
AbbVie raises annual profit forecast on strong Skyrizi sales	07:36am	RE
Tech Strength Boosts Wall Street Pre-Bell; Asia, Europe Up	07:23am	MT
Stocks Rebound Pre-Bell Ahead of Pending Inflation Report; Asia, Europe Gain	07:20am	MT
North American Morning Briefing : Tech Still in -2-	06:26am	DJ
Futures climb as Alphabet, Microsoft results lift megacaps	06:00am	RE
Cigna to offer Humira rivals with $0 copay at specialty pharmacy	Apr. 25	RE
AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint	Apr. 25	MT
AbbVie Inc. Announces Positive Topline Results from Level Up	Apr. 25	CI
Scholz promises support for pharma sector in Germany as Merck invests	Apr. 25	RE
US CDC warns of harmful reactions to fake Botox injections	Apr. 23	RE
Pfizer: new Emblaveo antibiotic approved in the EU	Apr. 22	CF
Sector Update: Health Care Stocks Advance Late Afternoon	Apr. 19	MT

Chart AbbVie Inc.

Duration

Period

More charts

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

167.3 USD

Average target price

184.1 USD

Spread / Average Target

+10.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+1.79%	296B
ELI LILLY AND COMPANY	+26.29%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.78%	331B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.12%	144B
PFIZER, INC.	-11.50%	143B

Other Pharmaceuticals

AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

AbbVie to Host Second-Quarter 2022 Earnings Conference Call

EPS Revisions